{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-268003","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.441213+00:00","generated_at":"2026-05-29T12:42:02.079370+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics CEO Scott Wolchko to retire Dec 31; succeeded by Bob Valamehr","bullets":["Wolchko resigned from board Nov 27, 2024; will retire as President & CEO effective Dec 31, 2024.","Valamehr, currently President of R&D, becomes President & CEO Jan 1, 2025; also named director.","Wolchko to remain a strategic advisor after retirement; resignation not due to any disagreement.","Valamehr has led iPSC platform development ~15 years; oversaw 13 IND applications and pipeline.","FT819 SLE trial: first patient achieved drug-free remission after single dose; no dose-limiting toxicities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-268003","json":"https://secwatch.observer/filing/0001193125-24-268003.json","markdown":"https://secwatch.observer/filing/0001193125-24-268003.md","text":"https://secwatch.observer/filing/0001193125-24-268003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524268003/0001193125-24-268003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524268003/d816234d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:42:02.079370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}